Robert Iannone, M.D., M.S.C.E, serves as the Executive Vice President and Global Head of Research and Development at Jazz Pharmaceuticals plc. Dr. Iannone is a seasoned pharmaceutical executive with a robust background in clinical development and medical affairs. He holds a medical degree from the University of Pennsylvania School of Medicine and a Master of Science in Clinical Epidemiology from the University of Pennsylvania. His career spans over two decades, during which he has held significant leadership roles in the pharmaceutical industry, notably at AstraZeneca and Wyeth Pharmaceuticals. At AstraZeneca, he served as Senior Vice President and Head of Respiratory, Inflammation, and Autoimmune iMed, where he was instrumental in advancing the company's portfolio in these therapeutic areas. At Jazz Pharmaceuticals, Dr. Iannone plays a pivotal role in steering the company's research and development strategy. Under his leadership, Jazz Pharmaceuticals has focused on developing innovative treatments for oncology, hematology, and neuroscience, aligning with the company's mission to address unmet medical needs. His strategic vision has been crucial in driving the company's growth and expanding its pipeline of novel therapies. Dr. Iannone's expertise in clinical development and his ability to foster collaborative research environments have been key to Jazz Pharmaceuticals' success in bringing new drugs to market. Dr. Iannone's achievements extend beyond his corporate roles; he is also an advocate for patient-centric drug development and has contributed to numerous publications in peer-reviewed journals. His commitment to advancing medical science and improving patient outcomes is evident in his work at Jazz Pharmaceuticals and his broader contributions to the field. As a leader in the pharmaceutical industry, Dr. Iannone continues to inspire and drive innovation, ensuring that Jazz Pharmaceuticals remains at the forefront of developing life-changing therapies.